查看購物車
  • Simplified Chinese
  • Japanese
  • Korean
分子即時診斷（mPOC）市場：市場展望與創新（2024-2029）
市場調查報告書
商品編碼
1669754

分子即時診斷（mPOC）市場：市場展望與創新（2024-2029）

Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029
出版日期: | 出版商: Kalorama Information | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

分子即時診斷（mPOC）徹底改變體外診斷（IVD）領域，提供分子檢測的靈敏度和特異性以及傳統即時診斷（POC）解決方案的可及性和速度。

mPOC 從一種新興技術創新轉變為一種主要的市場力量，其驅動力是急診室、門診診所、醫生辦公室和社區護理環境對快速準確的診斷解決方案的需求不斷成長。 COVID-19 疫情加速了技術的應用，特別是在呼吸道檢測領域，但市場仍在繼續擴展到新的領域，例如醫院內感染（HAI）、性傳染感染（STI）和熱帶疾病。

本報告調查分子即時診斷（mPOC）市場，對快速發展的市場的全面分析，涵蓋了至2029年五年的預測市場規模、成長前景、競爭格局等。

目錄

第1章 執行摘要

第2章 分子即時診斷市場的發展與趨勢

  • COVID-19 和分子 POC
  • 監理發展
  • 聯盟、資金和獎項
  • 業務
  • 分子即時診斷的優點和缺點
  • 理由：敏感度/特異性論點
  • 新系統和選單擴展
  • 交易與投資 mPOC 系統
  • 中國作為 POC 市場
  • POC 診斷中的常見測試和分析物
  • 分子即時診斷的基本技術
    • 微流體
    • 定量 PCR
    • 微陣列
    • 等溫擴增
    • 測試自動化
    • 引子和探針
    • 偵測
    • 新一代定序
    • 分子診斷
    • 即時 PCR（qPCR）
    • 等溫擴增法
    • 環介導等溫擴增（LAMP）
    • 切口酶擴增反應（NEAR）
    • 鏈置換擴增（SDA）
    • 解旋酶依賴性擴增（HDA）
    • 基於核酸序列的擴增（NASBA）
    • 轉錄介導擴增（TMA）
    • 交叉啟動擴增（CPA）
    • 線探針分析
  • 分子即時診斷應用與潛在應用
    • 分子 POC 診斷的主要測試
    • 流感
    • RIDT 的重新分類
    • 醫院內感染（HAI）
    • 鏈球菌A
    • 呼吸道合胞病毒（RSV）
    • 新用途
    • 茲卡病毒
    • 其他呼吸道感染
    • B 型鏈球菌
    • 人類乳突病毒
    • 單純皰疹病毒
    • 陰道炎
    • 肺結核
    • 瘧疾
    • 其他熱帶疾病和被忽視的疾病
    • 癌症
  • 歐洲設備法規

第3章 市場分析

  • 分子即時診斷市場分析
  • 區域市場佔有率
  • 依疾病領域細分
  • 床邊分子檢測市場
  • 床邊分子檢測供應商市場佔有率

第4章 公司簡介

  • Abbott Laboratories
  • Aidian Oy
  • Akonni Biosystems
  • binx health, inc.
  • Biocartis NV
  • bioMerieux SA
  • Cepheid (Danaher)
  • Credo Diagnostics Biomedical Pte. Ltd.
  • Curetis NV (OpGen)
  • DiaSorin S.p.A
  • GenMark Diagnostics (Roche)
  • Greiner Bio-One GmbH
  • Lucira Health (Pfizer)
  • Meridian Bioscience, Inc. (SD Biosensor)
  • Mesa Biotech, Inc. (Thermo)
  • QIAGEN NV
  • QuantuMDx Group
  • QuidelOrtho Corporation
  • Roche
  • Sekisui Diagnostics LLC
  • T2 Biosystems
簡介目錄
Product Code: 25-018KA

Molecular point-of-care (mPOC) diagnostics are revolutionizing the in vitro diagnostics (IVD) landscape, delivering the sensitivity and specificity of molecular testing with the accessibility and speed of traditional point-of-care (POC) solutions. Kalorama Information's latest report, "Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029", provides a comprehensive analysis of this rapidly evolving market, covering the size, growth trajectory, and competitive dynamics forecasted over a five year span to 2029.

Market Drivers & Opportunities

mPOC has transitioned from an emerging innovation to a major market force, driven by increasing demand for rapid and accurate diagnostic solutions in critical care units, outpatient clinics, physician offices, and community health settings. The COVID-19 pandemic accelerated adoption, particularly in the respiratory testing segment, but the market continues to expand into new areas, including hospital-acquired infections (HAIs), sexually transmitted infections (STIs), and tropical diseases.

With leading companies such as Abbott, Cepheid, bioMerieux, Roche, and QuidelOrtho competing in the space, this report explores key questions:

  • What is the size and projected growth of the mPOC market?
  • Which companies are leading the market, and how are they positioned?
  • How is mPOC impacting traditional laboratory-based molecular testing?
  • What regions and disease segments present the greatest opportunities?

Comprehensive Market Insights

This report offers detailed segmentation of the mPOC market, including:

  • Market Sizing & Forecasts (2024-2029) - Revenue projections by technology, region, and disease area.
  • Competitive Analysis - Market share breakdowns and insights into leading companies.
  • Geographic Trends - Market distribution across North America, Europe, Asia Pacific, and the Rest of the World.
  • Technology & Regulatory Landscape - Overview of CLIA-waived and moderate-complexity molecular platforms.

Scope

"Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029" provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings. This Kalorama Information report provides real-world analysis and modeling for relevant circumstances, with insights into near-patient molecular testing using small instruments.

This comprehensive analysis includes market shares for companies, regions, and disease types, distinguishing between "true" molecular point-of-care and near-patient molecular systems. The report highlights the competitive landscape, with major IVD companies and innovative players contributing to the market's growth. The report defines molecular point-of-care (mPOC) devices as those that run PCR or other DNA and RNA testing on a portable device, with features such as small footprint, fast result times, and usability outside of a reference lab.

A Decade of mPOC Research Expertise

Kalorama Information has been covering the mPOC market since its inception and provides real-world analysis rooted in extensive primary and secondary research. Whether you are an IVD company, investor, or healthcare provider "Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029", offers critical insights to help you navigate and capitalize on this fast-growing segment.

Table of Contents

Chapter 1: Executive Summary

  • Figure 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Figure 1-2: Near Patient Molecular Systems Market, 2024-2029 ($ million)
  • Where is Molecular Point-of-Care in 2025?
    • Table 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Molecular Point-of-Care Market Analysis
    • Table 1-2: Molecular Point-of-Care Market Growth, 2024-2029 (%)
    • Figure 1-3: Molecular Point-of-Care Market, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
  • Market Observations
  • "Near-Patient" Molecular Systems Market
    • Table 1-3: Near Patient Molecular Systems Market, 2024-2029 ($ million)
    • Table 1-4: Near Patient Molecular Systems Market Growth, 2024-2029 (%)
    • Table 1-5: mPOC and Near-Patient Market, 2024-2029 ($ million)
    • Figure 1-4: mPOC and Near-Patient Market, 2024-2029 ($ million)
  • Current Trends
  • Molecular Point-of-Care Diagnostics Defined
  • Usage of Molecular Point-of-Care
  • Leading mPOC Platforms
    • Table 1-6: Molecular POC Diagnostic Platforms and Technologies
  • Trends
  • Scope and Methodology

Chapter 2: Molecular Point-of-Care Market Development and Trends

  • COVID-19 and Molecular POC
    • Table 2-1: Molecular POC COVID-19 Emergency Authorizations
    • CDC Initial Response, Long Term Situation
    • COVID-19's Unique Challenge
    • BARDA Directs Funding to mPOC
  • Regulatory Developments
  • Consortia, Funding, Prizes
  • Deals
    • Table 2-2: Deals in Molecular Point-of-Care, April 2019-Feb 2025
  • Advantages and Disadvantages of Molecular Point-of-Care
    • Table 2-3: Disadvantages of Molecular Point-of-Care, by Setting [Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC]
  • Justification: The Sensitivity/Specificity Argument
  • New Systems and Menu Expansion
    • New Systems Introduced in Development
    • Combination Tests Changing Market: SARS-CoV-2, Flu A, Flu B, and RSV
    • STI Continues to Be a Growth Area
  • Deals, Investment in mPOC Systems
    • Roche Acquires LumiraDx for up to $350 Million
    • Thermo Acquires Mesa Biotech
  • China as a POC Market
  • Common Tests and Analytes in POC Diagnostics
  • Component Technologies of Molecular Point-of-Care Diagnostics
    • Microfluidics
    • qPCR
    • Microarrays
    • Isothermal Amplification
    • Test Automation
    • Primers and Probes
    • Detection
    • Next-Generation Sequencing
    • Molecular Diagnostics
    • Real-Time PCR (qPCR)
    • Isothermal Amplification Methods
    • Loop-Mediated Isothermal Amplification (LAMP)
    • Nicking Enzyme Amplification Reaction (NEAR)
    • Strand Displacement Amplification (SDA)
    • Helicase Dependent Amplification (HDA)
    • Nucleic Acid Sequence-Based Amplification (NASBA)
    • Transcription-Mediated Amplification (TMA)
    • Cross Priming Amplification (CPA)
    • Line Probe Assays
  • Applications and Potential Applications for Molecular Point-of-Care
    • Major Testing Applications for Molecular POC Diagnostics
    • Influenza
    • Reclassification of RIDTs
    • Hospital-Acquired Infections (HAIs)
    • Strep A
    • Respiratory Syncytial Virus (RSV)
    • Emerging Applications
    • Zika
    • Other Respiratory Infections
    • Group B Streptococcus
    • Human Papillomavirus
    • Herpes Simplex Virus
    • Vaginitis
    • Tuberculosis
    • Malaria
    • Other Tropical and Neglected Diseases
    • Cancer
  • European Device Regulations

Chapter 3: Market Analysis

  • Molecular Point-of-Care Market Analysis
    • Table 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
    • Figure 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Regional Shares
    • Table 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
    • Figure 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
    • Figure 3-3: Global Molecular Point-of-Care Market Share, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
  • Breakout by Disease Area
    • Table 3-3: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
    • Figure 3-4: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
    • Figure 3-5: Breakout of Molecular Point-of-Care Market Share, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
  • "Near Patient Molecular" Market
    • Table 3-4: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
    • Figure 3-6: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Vendor Market Share for Near Patient Molecular Testing
    • Table 3-5: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMerieux, Cepheid, Roche, Other]
    • Figure 3-7: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMerieux, Cepheid, Roche, Other]

Chapter 4: Company Profiles

  • Abbott Laboratories
  • Aidian Oy
  • Akonni Biosystems
  • binx health, inc.
  • Biocartis NV
  • bioMerieux SA
    • Table 4-1: bioMerieux FilmArray Est. Systems per Quarter, Q4 '18-Q4 '24
    • Figure 4-1: FilmArray Systems Installed by Quarter, Q4 2018-Q4 2024
  • Cepheid (Danaher)
    • Molecular Healthcare-Acquired Infection (HAI) Testing
    • Molecular Sexual Health and Women's Health Testing
    • Molecular Critical Infectious Disease Testing
    • Molecular Oncology/Genetics Testing
  • Credo Diagnostics Biomedical Pte. Ltd.
  • Curetis NV (OpGen)
  • DiaSorin S.p.A
  • GenMark Diagnostics (Roche)
  • Greiner Bio-One GmbH
  • Lucira Health (Pfizer)
  • Meridian Bioscience, Inc. (SD Biosensor)
  • Mesa Biotech, Inc. (Thermo)
  • QIAGEN NV
  • QuantuMDx Group
  • QuidelOrtho Corporation
  • Roche
  • Sekisui Diagnostics LLC
  • T2 Biosystems